Japan, July 14 -- ONCOCEUTICS INC has got intellectual property rights for 'IMIPRIDONE FOR GLIOMA.' Other related details are as follows:
Application Number: JP,2023-118821
Category (FI): A61K31/519,A61P35/00
Stage: PROBLEM TO BE SOLVED: To provide imipridone for glioma.SOLUTION: In particular, imipridone selectively modulates class A G protein-coupled receptors (GPCRs), such as the D2-like subfamily of dopamine receptors, and may be used to treat conditions and disorders in need of such modulation, such as cancer. In particular, the cancers relate to the midline structure of the brain, cancers with histone H3 mutations, or both. In addition, methods of identifying whether a subject having these conditions is likely to respond to a treatment regimen, such as imipridone administration, are provided. In addition, methods of assessing the effectiveness of a treatment regimen, such as administration of imipridone, monitoring subjects suffering from these conditions, or providing prognosis for subjects suffering from these conditions are also provided.SELECTED DRAWING: Figure 18 (Grant)
Filing Date: July 21, 2023
Publication Date: Oct. 3, 2023
The original document can be viewed at: https://www.j-platpat.inpit.go.jp/p0100
Disclaimer: Curated by HT Syndication.
